Literature DB >> 18196345

Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.

Anne Brecht Francken1, Neil A Accortt, Helen M Shaw, Martin Wiener, Seng-jaw Soong, Harald J Hoekstra, John F Thompson.   

Abstract

OBJECTIVE: Information on prognosis for patients with cutaneous melanoma after locoregional or distant recurrence is sparse and controversial. The aim of this study was to analyze factors influencing outcome after the development of a first relapse.
METHODS: Information was extracted from the Sydney Melanoma Unit database for 873 melanoma patients with American Joint Committee on Cancer (AJCC) Stage I and II disease treated between 1960 and 2002 who relapsed following treatment of their primary melanoma. Clinical and pathologic factors predicting survival were analyzed using the Cox proportional hazards regression model.
RESULTS: Initial presentation of recurrence was local: 95 patients (10.9%), in transit: 86 patients (9.9%), regional lymph node: 300 patients (34.4%), and distant: 392 patients (44.9%). Independent prognostic factors for survival of the 481 patients with only locoregional recurrence were type of recurrence, primary tumor ulceration, and patient age. Predictors for longer survival in the 392 patients with distant metastasis at the time of first presentation with recurrence were lung vs other sites and diagnosis of relapse after 1990 compared with diagnosis before 1980.
CONCLUSIONS: The type of recurrence is the most important prognostic factor in melanoma patients who relapse. Primary tumor ulceration is the most important pathologic predictor. The results of this study suggest that management of distant metastases may have improved over the last 25 years, but many confounders and improved staging techniques make assessment of this unreliable.

Entities:  

Mesh:

Year:  2008        PMID: 18196345     DOI: 10.1245/s10434-007-9717-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  27 in total

1.  Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival.

Authors:  Rajmohan Murali; Richard A Scolyer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

2.  Melanoma MicroRNA signature predicts post-recurrence survival.

Authors:  Miguel F Segura; Ilana Belitskaya-Lévy; Amy E Rose; Jan Zakrzewski; Avital Gaziel; Douglas Hanniford; Farbod Darvishian; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Iman Osman; Eva Hernando
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 3.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 4.  Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.

Authors:  Nigel Fleeman; Adrian Bagust; Sophie Beale; Angela Boland; Rumona Dickson; Kerry Dwan; Marty Richardson; Yenal Dundar; Helen Davis; Lindsay Banks
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

5.  Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma.

Authors:  Travis E Grotz; Svetomir N Markovic; Lori A Erickson; William S Harmsen; Marianne Huebner; David R Farley; Barbara A Pockaj; John H Donohue; Franklin H Sim; Clive S Grant; Sanjay P Bagaria; Thomas C Shives; Charles M Balch; James W Jakub
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

6.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

7.  A high proliferative index of recurrent melanoma is associated with worse survival.

Authors:  Ting J Tu; Michelle W Ma; Stefano Monni; Amy E Rose; Herman Yee; Farbod Darvishian; David Polsky; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Madhu Mazumdar; Iman Osman
Journal:  Oncology       Date:  2011-06-24       Impact factor: 2.935

8.  Malignant melanoma of the skin: long-term follow-up and time to first recurrence.

Authors:  Annika M Hohnheiser; Olaf Gefeller; Jonas Göhl; Gerold Schuler; Werner Hohenberger; Susanne Merkel
Journal:  World J Surg       Date:  2011-03       Impact factor: 3.352

9.  Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study.

Authors:  Gerd Grözinger; Steven Mann; Tarun Mehra; Bernhard Klumpp; Ulrich Grosse; Konstantin Nikolaou; Claus Garbe; Stephan Clasen
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

10.  A gene expression signature of invasive potential in metastatic melanoma cells.

Authors:  Aaron R Jeffs; Amy C Glover; Lynn J Slobbe; Li Wang; Shujie He; Jody A Hazlett; Anshul Awasthi; Adele G Woolley; Elaine S Marshall; Wayne R Joseph; Cristin G Print; Bruce C Baguley; Michael R Eccles
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.